Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer
Immuneering Corporation Class A Common Stock · PHARMACEUTICAL PREPARATIONS · Now $4.49
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS